Modern biopharmaceuticals : (Record no. 20480)

MARC details
000 -LEADER
fixed length control field 04663cam a2200589Ma 4500
001 - CONTROL NUMBER
control field ocn842412695
003 - CONTROL NUMBER IDENTIFIER
control field OCoLC
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20230823095613.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION
fixed length control field m o d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr |n||||||||a
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 110329s2013 gw fo 000 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency CDX
Language of cataloging eng
Description conventions pn
Transcribing agency CDX
Modifying agency DG1
-- YDXCP
-- NOC
-- OCLCQ
-- OCLCO
-- OCLCF
-- OCLCQ
-- EBLCP
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
ISBN 9783527669417
Qualifying information (electronic bk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
ISBN 3527669418
Qualifying information (electronic bk.)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
ISBN 9781299448902
Qualifying information (MyiLibrary)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
ISBN 1299448909
Qualifying information (MyiLibrary)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Cancelled/invalid ISBN 9783527322831
Qualifying information (Cloth)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Cancelled/invalid ISBN 3527322833
Qualifying information (Cloth)
029 1# - (OCLC)
OCLC library identifier AU@
System control number 000051629414
029 1# - (OCLC)
OCLC library identifier CHBIS
System control number 010026923
029 1# - (OCLC)
OCLC library identifier CHVBK
System control number 30623761X
029 1# - (OCLC)
OCLC library identifier DEBBG
System control number BV043395820
029 1# - (OCLC)
OCLC library identifier GBVCP
System control number 790207273
029 1# - (OCLC)
OCLC library identifier NZ1
System control number 15340137
029 1# - (OCLC)
OCLC library identifier NZ1
System control number 15905464
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)842412695
037 ## - SOURCE OF ACQUISITION
Stock number 476140
Source of stock number/acquisition MIL
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RM301.4
060 #4 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER
Classification number QV 38
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 615.1/9
Edition number 22
049 ## - LOCAL HOLDINGS (OCLC)
Holding library MAIN
245 00 - TITLE STATEMENT
Title Modern biopharmaceuticals :
Remainder of title recent success stories /
Statement of responsibility, etc edited by Jorg Knablein.
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Place of publication, distribution, etc Weinheim :
Name of publisher, distributor, etc Wiley-VCH Verlag GmbH,
Date of publication, distribution, etc 2013.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (450 pages)
336 ## -
-- text
-- txt
-- rdacontent
337 ## -
-- computer
-- c
-- rdamedia
338 ## -
-- online resource
-- cr
-- rdacarrier
588 0# -
-- Print version record.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Related Titles; Title Page; Copyright; Dedication; Foreword by Andreas Busch; Foreword by Günter Stock; Preface; Quotes; List of Contributors; Part I: Modern Biopharmaceuticals: Research is the Best Medicine -- Sanitas Summum Bonus; Chapter 1: Twenty Thousand Years of Biotech -- From "Traditional" to "Modern Biotechnology"; 1.1 Biotechnology -- The Science Creating Life; 1.2 The Inauguration of Biotechnology; 1.3 From "Traditional" to "Modern Biotechnology"; 1.4 A Small Molecule from Bacteria -- A Huge Importance for Mankind; 1.5 Biopharmaceuticals -- The Mainstay of Modern Biotechnology
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 1.6 Transformation of the Pharma Industry Through Biotechnology1.7 Biopharmaceutical Production -- Uncorking Bottlenecks or Wasting Surplus Capacity?; 1.8 Conclusion and Outlook; References; Part II: Modern Biopharmaceutical Development Using Stem Cells, Tissues, and Whole Animals; Chapter 2: Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer? -- The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals; 2.1 Introduction; 2.2 Derivation and Growth of hESC; 2.3 Signaling Pathways and Transcription Factors
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 2.4 Differentiation and Applications of hESC2.5 Patient-Specific Nuclear Transfer Stem Cells; 2.6 Patient-Specific Pluripotent Cells Through Direct Reprogramming of Adult Somatic Cells; 2.7 Concluding Remarks and Outlook; Acknowledgment; References; Chapter 3: Pluripotent Stem Cell-Derived Cardiomyocytes for Industrial and Clinical Applications; 3.1 Introduction; 3.2 Pluripotent Stem Cells; 3.3 High-Yield Differentiation of Pluripotent Stem Cells into Cardiomyocytes; 3.4 Purification of Pluripotent Stem Cell-Derived Cardiomyocytes; 3.5 Cardiomyocytes at an Industrial Scale
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note 3.6 Utilization of Tissue Engineering Technologies to Advance Cellular Maturity3.7 Concluding Remarks; References; Chapter 4: Industrialization of Functional Mouse Genomics Technologies for Biopharmaceutical Drug Discovery and Development; 4.1 Introduction; 4.2 The Mouse Genetics Story; 4.3 Establishing Inducible Gene Targeting Tools; 4.4 RNAi -- Talking About a Revolution?; 4.5 Further Shortening the Generation Timeline for RNAi Mouse Models; 4.6 Adapting the Mouse Genetics Toolbox for New Applications; References; Part III: Innovative Development Tools for Modern Biopharmaceuticals
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note Chapter 5: Standardized Solutions for Quantitative and Real-Time RT-PCR to Accelerate Biopharmaceutical Development5.1 Introduction; 5.2 Potential of Real-Time RT-PCR in Biopharmaceutical Development; 5.3 Accurate Gene Expression Analysis Depends on Standardized Preanalytical Steps; 5.4 Accuracy of Real-Time RT-PCR Depends on Efficient cDNA Synthesis; 5.5 Integration of Preanalytical Steps Streamlines Gene Expression Analysis; 5.6 Overview of Methods for Real-Time RT-PCR; 5.7 Developments in Real-Time PCR Instrumentation; 5.8 The Need for Better Standardization of Quantification Methods
526 ## - STUDY PROGRAM INFORMATION NOTE
Department Biotechnology & Bioinformatics
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Biopharmaceutics.
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Biopharmaceutics.
Source of heading or term fast
-- (OCoLC)fst00832650
655 #4 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Electronic books.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Knäblein, Jörg.
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Print version:
International Standard Book Number 9781299448902
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://dx.doi.org/10.1002/9783527669417">http://dx.doi.org/10.1002/9783527669417</a>
Public note Wiley Online Library
994 ## -
-- 92
-- DG1

No items available.